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During the COVID-19 pandemic, the need for noninvasive respiratory support devices has dramatically 
increased, sometimes exceeding hospital capacity. The full-face Decathlon snorkeling mask, 
EasyBreath (EB mask), has been adapted to deliver continuous positive airway pressure (CPAP) as an 
emergency respiratory interface. We aimed to assess the performance of this modified EB mask and 
to test its use during different gas mixture supplies. CPAP set at 5, 10, and 15  cmH2O was delivered 
to 10 healthy volunteers with a high-flow system generator set at 40, 80, and 120 L  min−1 and with a 
turbine-driven ventilator during both spontaneous and loaded (resistor) breathing. Inspiratory  CO2 
partial pressure  (PiCO2), pressure inside the mask, breathing pattern and electrical activity of the 
diaphragm (EAdi) were measured at all combinations of CPAP/flows delivered, with and without the 
resistor. Using the high-flow generator set at 40 L  min−1, the  PiCO2 significantly increased and the 
system was unable to maintain the target CPAP of 10 and 15  cmH2O and a stable pressure within the 
respiratory cycle; conversely, the turbine-driven ventilator did. EAdi significantly increased with flow 
rates of 40 and 80 L  min−1 but not at 120 L  min−1 and with the turbine-driven ventilator. EB mask can 
be safely used to deliver CPAP only under strict constraints, using either a high-flow generator at a 
flow rate greater than 80 L  min−1, or a high-performance turbine-driven ventilator.
Hospitals and physicians worldwide are facing a new health emergency as a consequence of the coronavirus dis-
eases 2019 (COVID-19)  pandemic1 that has spread enormously  worldwide2, placing an extraordinary demand on 
the health-care systems. Approximately 30% of hospitalized patients with COVID-19 develop acute hypoxemic 
respiratory failure (AHRF) requiring oxygen and noninvasive respiratory support (NRS). About 5% of them 
require invasive mechanical ventilation (IMV) and intensive care unit (ICU)  admission3–5.
Healthcare organizations have proactively implemented several strategies to supply shortages of equipment 
as demand surges, rationing life-saving treatments such as using shared mechanical  ventilation6, establishing 
ventilator lottery or ventilator triage  policies7,8, and increasing the use of  NRS9. To address the high demand for 
NRS equipment exceeding the capacity, Food and Drug Administration issued an emergency policy allowing 
the use of home respiratory devices, such as Continuous Positive Airway Pressure (CPAP), as an alternative to 
life-saving  ventilators10.
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The need to ensure the availability of the highest possible number of CPAP devices also led a group of engi-
neers from northern Italy to build an “emergency ventilator mask”, converting full face snorkeling masks into 
interfaces that can be used to apply CPAP  therapy11. Nevertheless, innovative and potentially life-saving products 
not previously tested and approved for clinical use can cause serious adverse effects.
Thus, the present study aimed to assess the technical performance of a modified commercial surface snor-
keling mask EasyBreath (EB mask), (Decathlon, Villeneuve-d’Ascq, France) that has been used in COVID-19 
patients for delivering CPAP. The aim of this study was to test its use during different gas mixture supplies, 
evaluating the stability of pressure generated and the amount of carbon dioxide  (CO2) rebreathing inside the EB 
mask during spontaneously and resistive loaded breathing in healthy volunteers.
Results
Ten healthy volunteers (eight males and two females), with age comprised between 27 and 45 years old and a 
mean body mass index (BMI) of 24 kg/m2 completed the study. None of the subjects complained about discom-
fort or fogging of the interface.
The  FiO2 delivered during CPAP with the flow generator was between 31 and 34%, depending on the flow/
PEEP combination. During CPAP delivered with the turbine-driven ventilator, the  FiO2 ranged from 30 to 35%.
The  PiCO2 ranged from 0 to 7 mmHg, depending on the flow/CPAP level combination used (p < 0.01, ANOVA 
for repeated measurements), as shown in Table 1. The highest  PiCO2 was recorded at 40 L  min−1 of fresh gas 
flow with CPAP 15  cmH20 and it decreased progressively to 0 (undetectable) as the fresh gas flow increased up 
to 120 L  min−1 or using the turbine-driven ventilator, independently of the CPAP level.
The pressures inside the mask at different flows/PEEP are shown in Fig. 1. Target CPAP was not achieved 
when the oxygen-driven flow generator delivered 40 L  min−1. Only the highest flow tested (120 L  min−1) allowed 
the achievement of all the CPAP levels tested (5,10,15  cmH2O), even if some over-treatment was obtained at 
CPAP 5 and 10  cmH2O (+ 119% and + 35%, respectively). By contrast, the turbine-driven ventilator allowed the 
maintenance of target CPAP levels throughout the protocol.
Supplementary Table S2 also shows actual CPAP partitioned between the inspiratory and expiratory phase, 
as referenced to target CPAP. Only the turbine ventilator succeeded in keeping the actual CPAP level close to its 
target value both at end-expiration and at end-inspiration for all the CPAP levels tested, the pressure difference 
between end-inspiration and end-expiration being maintained within 2  cmH2O. Statistically and clinically worse 
was the performance of the high-flow generator in this task. As a matter of fact, at a flow of 40 L  min−1, neither 
end-inspiratory nor end-expiratory pressures reached the target CPAP. In contrast, at 80 and 120 L  min−1, the 
actual pressure was above its target level at end-expiration and below it at end-inspiration, with the difference 
between these two conditions being well above 2  cmH2O. Similar results were obtained for both loaded and 
unloaded breathing (Supplementary Table S2).
The respiratory pattern (flows, volume, and respiratory timing) and the EAdi recorded at baseline and at dif-
ferent experimental conditions, with and without the use of the resistor, are shown in Supplementary Table S1 
and Fig. 2. In comparison to baseline, minute ventilation remained stable with the CPAP mask at any level of 
pressure applied during unloaded breathing. By contrast, it significantly decreased during loaded breathing 
because of a significant reduction of tidal volume. Respiratory rate remained constant throughout the protocol 
(Supplementary Table S1).
Diaphragmatic electrical activity increased with any CPAP level compared to baseline, either in terms of 
EAdi  InspAUC  and EAdi/VT (Fig. 2). During loaded breathing, EAdi increased by a similar amount in all the 
conditions tested.
Discussion
The present study showed that the use of a modified EB mask coupled with a high-flow generator: (1) induces 
substantial  CO2 rebreathing when set at a flow rate below 80 L  min−1, (2) fails to achieve CPAP levels higher than 5 
 cmH2O if set at a flow rate of 40 L  min−1 and (3) increases diaphragm’s electrical activation (hence, diaphragmatic 
energy expenditure) due to pressure instability along the respiratory cycle. These adverse effects disappear using 
high flows (> 80 L  min−1) or a high-performance turbine-driven ventilator set in CPAP mode.
The use of repurposed devices to fend off the shortage of ventilators during the current COVID-19 pandemic, 
without prior evidence of efficacy, is an issue of increasing  concern12. Manufacturers can market medical devices 
without proof of their effectiveness, especially in urgent unusual circumstances like the COVID-19  pandemic13. 
Indeed, the emergency may force clinicians to adopt unregistered interfaces, such as the popular EB mask, to 
deliver ventilatory support to patients, with little or no prior tests of performance. To the best of our knowledge, 
this is the first study that fills this knowledge gap after introducing the modified EB mask for CPAP delivery.
Table 1.  Inspiratory  CO2 partial pressure at different flow rate and PEEP level. CPAP continuous positive 
airway pressure, SD standard deviation, PEEP positive end expiratory pressure, Astral 150 turbine-driven 
ventilator. p value ANOVA for repeated measures (same CPAP level with different flow).
CPAP level  (cmH20)
40 L  min−1
Mean (SD)
80 L  min−1
Mean (SD)
120 L min −1
Mean (SD)
Astral 150
Mean (SD) p value
5 5 (0.9) 1.2 (0.7) 0 (0) 0 (0) < 0.01
10 6.5 (1.3) 1.9 (0.8) 0 (0) 0 (0) < 0.01
15 7 (1.5) 3.2 (1.4) 0 (0) 0 (0) < 0.01
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:5559  | https://doi.org/10.1038/s41598-021-85093-w
www.nature.com/scientificreports/
Using CPAP in AHRF has the principal aim to improve gas exchange, increasing the end-expiratory lung 
volume (EELV) and avoiding the inspiratory elastic threshold-load imposed by the increased  EELV14, also when 
applied non-invasively15,16. However, some interfaces can provoke  CO2 rebreathing if misused, thus impairing 
treatment  effectiveness17.
CO2 rebreathing. EB mask has a wide dead-space (about 800–900 mL), and thus, given a fixed  CO2 produc-
tion, it requires high flows to wash-out the exhaled  CO2 completely, as with other high dead-space  interfaces17. 
Figure 1.  Pressure recorded inside the mask. Upper whiskers represent the average expiratory peak pressure 
at end-expiration. Lower whiskers represent the mean pressure at the average inspiratory peak pressure at end-
inspiration; circles represent the mean pressure computed throughout the respiratory cycle; redline represents 
the set CPAP level.
Figure 2.  Electrical diaphragm effort. EAdi/VT, electrical diaphragm activity area of the inspiratory phase 
normalized for the tidal volume  (VT); EAdi  InspAUC, electrical diaphragm activity area of the inspiratory phase.
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CPAP flow rate of 120 L  min−1 or flows guaranteed by a high-performance turbine-driven ventilator completely 
flushed out  CO2. Remarkably, if the gas flow is not high enough to generate pressures able to keep the PEEP 
valve open, the  CO2 wash-out is not guaranteed. Thus, in case of emergency use of the EB mask, the first caveat 
is to use very high flows of fresh gas (about fourfold the peak inspiratory flow) in the circuit, whatever its source.
Effectiveness in achieving target CPAP. An ideal CPAP system, by definition, should provide a target 
positive airway pressure through the respiratory cycle to improve alveolar recruitment and gas exchange. Con-
versely, our data showed that although the pressure inside the EB mask never dropped below zero during the 
inspiratory phase, it always remained far below the set CPAP level when using a fresh gas flow of 40 L  min−1, 
indicating that at this target inspiratory flow the PEEP valve was closed and, thus, malfunctioning. Such low 
driving flows should be avoided and properly increased to maintain the airflow through the PEEP valve through-
out the respiratory cycle (driving flow greater than 80 L  min−1 in the present study). On the other hand, during 
the expiratory phase, the pressure level recorded at the highest rate of fresh gas flow (120 L  min−1) overcame 
the set CPAP level, at least at 5 and 10  cmH2O, potentially generating an undue increase in end-expiratory lung 
volume. This is probably due to the performance of the PEEP valve at high flow (120 L  min−1) since when the 
total flow (fresh gas flow + expiratory flow) exceeds the capacity of the PEEP valve, pressure becomes “flow-
dependent”18. Fresh gas flow of 80 L  min−1 performed in the middle, overcoming the set pressure of 5  cmH2O 
and under-assisting at the target CPAP of 15  cmH2O.
Mechanical ventilators are the most sophisticated devices to administer CPAP. However, old devices per-
formed worse than high flow generators in delivering stable CPAP levels, mainly because of the demand-valve 
 technology19. The newer generation of ventilators has complex flow algorithms that allow for a more aggressive 
flow modulation and delivery flows using single circuits with intentional leaks designed to stabilize airway pres-
sure and lessen the imposed work of  breathing15. This was the case in our study when CPAP was delivered with 
the turbine-driven ventilator provided with an intentional leak circuit (EB mask + turbine-ventilator + single 
circuit + intentional leak), where we recorded a stable pressure at any level of target CPAP tested.
Diaphragmatic activity and effort. An ideal CPAP system should provide a constant positive airway 
pressure throughout the respiratory cycle to avoid negative effects on the work of  breathing20,21 since large pres-
sure swings around the set PEEP level are associated with increased respiratory  efforts22. Our study showed 
that end-inspiratory to end-expiratory pressure swing was clinically relevant (above 3  cmH20) at all set levels of 
CPAP and flows when using the high flow generator with a flow rate lower than 80 L  min−1. We observed this 
phenomenon notwithstanding the presence of a reservoir bag and a threshold PEEP valve in the CPAP circuit 
that should maintain the pressure stable, whatever is the flow passing through it. Pressure swings occurring 
across target CPAP levels imply wasted patients’ respiratory effort spent against CPAP device, ineffective in 
producing flow and  volume19. As a matter of fact, EAdi inspiratory activity and, hence, diaphragmatic  effort23 
increased with CPAP application compared to baseline in all the study conditions (with or without resistive load-
ing) when high flow CPAP generator delivered flows of 40 and 80 L  min−1. This result confirms previous data 
showing increased work of breathing during CPAP  application24, and suggesting a suboptimal performance of 
high flow CPAP  generators18,25.
EAdi increase can be due to CPAP system-induced extended workload, on a  CO2 rebreathing-induced 
increase of respiratory drive, or a combination of both. The inspiratory EAdi-time product (EAdi InspAUC) 
increased by 45% during CPAP application and only 35% when normalized for  VT, implying that both the 
above-quoted mechanisms contributed to the overall increase of EAdi activity during EB mask CPAP delivery, 
compared to spontaneous breathing. The increase of diaphragmatic electrical activity (and effort) disappeared 
during both CPAP set at the highest flow (120 L  min−1) and delivered by the turbine ventilator showing that 
considering these constraints is crucial in EB mask emergency use.
This study should be a warning sign against the indiscriminate use of tools to deliver noninvasive respiratory 
support without rigorous performance tests.
Strengths and limitations. The main strength of our study is the rigorous evaluation of several param-
eters of performance (i.e.  PiCO2, Pmask, EAdi) at three different levels of flow, recreating the setup used in clinics 
for noninvasive ventilatory support in COVID-19 patients.
The present study has several limitations. First, this was a proof-of-concept study performed in healthy vol-
unteers; therefore, it may not reflect the dynamic nature of ventilation parameters during severe acute respiratory 
syndrome. However, simulating loaded breathing, we partially overcame this limitation. Second, we did not 
compare the new device against a ‘gold standard’. Thus, up to now, it is only clear that the EB mask works properly 
only under strictly controlled conditions. Still, it is impossible to state whether it is inferior/superior to reference 
interfaces. Finally, the  PiCO2 was stable during the conditions tested, but the recordings lasted only 2 min each. 
Therefore, we cannot ensure that these values would have remained stable for a longer period.
Conclusion
The modified Decathlon’s EB mask should be used for emergency use to deliver CPAP only under strict con-
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Methods
Study design. We designed a physiological study involving ten healthy volunteers recruited among physi-
cians at the Department of Anesthesia and Critical Care, Policlinico "G. Martino," University of Messina, Italy, 
in June 2020. The study was approved by the Ethics committee of Policlinico G. Martino, Messina, Italy (32-30 
27/05/2020). All the study participants provided written informed consent. All methods were performed in 
accordance with relevant guidelines and regulations.
Experimental set-up and study devices. The experimental set-up is illustrated in Fig. 3. We used a 
modified Decathlon’s EasyBreath (EB mask) surface snorkeling mask (Decathlon, Villeneuve-d’Ascq, France) 
as a full-face mask to deliver CPAP. The original valve set on the chin was modified to be permanently closed, 
allowing all exhaled air to be evacuated through the two lateral channels of the mask to the top of the  snorkel26. 
Unlike conventional interfaces used in clinical practice, this mask has two different compartments inside; the 
upper one for the eyes, dedicated to the vision, and the lower one for the mouth and nose, dedicated to the 
breathing. The original EB mask snorkel was replaced with a 3D printed adaptor, the Charlotte valve, patented 
by ISINNOVA (Brescia, Italy), to connect the mask to an oxygen-driven flow generator. This valve has an inlet 
line connected to the oxygen and an outlet line connected to a threshold resistor [Positive End Expiratory Pres-
sure (PEEP) valve], as shown in Supplementary Fig. S1. An HEPA filter (DAR™ Mechanical Filter Compact) was 
added to a breathing circuit of 120 cm.  FiO2 was kept constant with a range of 30–35% (measured with oxy-
sensor inside the mask), to avoid extra variability to the experiment.
The internal volume was measured by filling the mask with water when applied to the volunteers’ face, as 
previously  described27, and amounted to 880 ± 11 mL.
To allow measurements, the experimental setting included the following items (Fig. 3):
1. a pneumotachograph (V.T. mobile; Fluke Biomedical, Everett, WA, USA) to measure ventilatory airflow, 
connected with a serial interface to a laptop for recording (V.T. for Windows Software version 2.01.07, Fluke 
Biomedical, Everett, WA, USA);
2. a side-stream capnometer (CO2SMO plus; Novametrix Medical System, Wallingford, Connecticut, USA) to 
measure inspiratory carbon dioxide tension  (PiCO2);
3. a dedicated nasogastric tube with a built-in multiple array esophageal electrode (Edi catheter) to monitor 
diaphragm  activity14. It was connected to a Servo-I ventilator (Getinge, Solna, Sweden), equipped with 
Neurally Adjusted Ventilatory Assist (NAVA) (Getinge, Solna, Sweden), linked through a serial interface to 
a laptop with dedicated software (Servo-tracker version 4.2, Getinge, Solna, Sweden).
4. a pressure transducer (coupled to the V.T. mobile, through an auxiliary port) to measure the pressure inside 
the mask (Pmask) connected to the laptop for recording.
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All the instruments underwent testing and calibration according to the manufacturers’ specifications before 
performing all the measurements.
Measurements and recordings. Based on the experimental set-up, the following variables were meas-
ured: (1)  PiCO2; (2) Minute ventilation; (3) Pmask; (4) electrical diaphragm activity (EAdi).
Each volunteer was studied placed comfortably in a semi-recumbent position and performed all the tests on 
the same day in random order. Volunteers were first allowed to adapt to CPAP breathing before the recordings.
At baseline, two, 120 s each, recordings of breathing pattern and EAdi were carried out without the mask. The 
first one during quiet unloaded breathing, and the second while breathing through an inline resistor (connected 
to the mouthpiece) made with an endotracheal tube connector with an inner diameter of 5 mm, to simulate an 
increase of respiratory load.
After tightly fitting to the volunteers’ face the modified EB  mask11, leaks were minimized by sealing the mask 
chin valve around all measurement lines. Two sets of measurements were performed while delivering CPAP 
with two different systems:
1. a CPAP flow generator (Whisperflow 2, Respironics), connected to the 3D printed Charlotte  valve11 attached 
to the mask. A reservoir bag inserted in the inspiratory line was used to minimize airway pressure variations. 
An adjustable PEEP valve (Ambu, Denmark) added to the Charlotte valve’s expiratory port provided the 
PEEP level.  PiCO2, Pmask, flow lines, and the Edi catheter were inserted into the mask through the sealed 
chin valve (Fig. 3). CPAP was set at three different flow rates (40, 80, 120 L  min−1) and for each flow, three 
different PEEP levels were employed (5, 10, 15  cmH2O), with and without the resistor in place (load);
2. a turbine-driven home care mechanical ventilator (Astral 150, Resmed, San Diego, USA) set in CPAP mode at 
three different PEEP levels: 5, 10, 15  cmH20. CPAP was administered with a single limb vented configuration 
with an intentional leak (a tube connector with an inner diameter of 5.5 mm) placed on the Charlotte valve’s 
expiratory port. Low-pressure oxygen was provided to the turbine-driven ventilator through a dedicated 
port in order to obtain the same  FiO2 used to drive the flow generator.
The total length of breathing circuit was 120 cm. A 120 s-trial was recorded for each session for off-line 
analysis. No instructions were given to the subjects regarding the breathing pattern to adopt.
Data analysis. A Matlab (version 9.7.0.1190202, The MathWorks Inc., Natick, Massachusetts, USA) auto-
matic procedure was developed to find maximal and minimum EAdi (Fig. 4) and pressure for each breath. The 
EAdi-time product, measured as the EAdi curve area from the beginning to the end of an inspiratory cycle (EAdi 
 InspAUC ), was calculated (Fig. 4). The EAdi  InspAUC  was then normalized for the tidal volume  (VT), (EAdi /VT). 
Figure 4.  Matlab automatic EAdi analysis. EAdi electrical diaphragm activity, EAdimax peak electrical 
diaphragm activity, EAdimin electrical diaphragm activity, EAdi InspAUC  electrical diaphragm activity area of 
the inspiratory phase, EAdi Tin inspiratory time derived from electrical diaphragm activity, EAdi Ttot total 
respiratory time derived from electrical diaphragm activity.
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Average end-expiration and end-inspiration peak pressures were calculated for every recording session. The 
same was also done for the  EAdimax, EAdi  InspAUC, and EAdi /VT. For each recording session, the average delta 
pressure inside the mask at the end-expiration (ΔPmask Exp = Pmask end-expiratory − CPAP Level) and end-
inspiration (ΔPmask Insp = Pmask end-inspiratory − CPAP Level) were computed.
The distribution of each continuous variable was initially tested with the Shapiro–Wilk test for normality. 
Results are expressed as mean ± SD when normally distributed, otherwise as median and interquartile range. 
Based on preliminary measurements, we estimated that 10 healthy subjects were necessary to detect, with a 0.8 
power, a significant difference (α = 0.05) on airway pressure drop during inspiration (ΔPmask Insp). Comparisons 
of ΔPmask at different flows and for each CPAP level were assessed using the analysis of variance (ANOVA) for 
repeated measures. The statistical analysis was performed using (SPSS 24, IBM) software. A p value < 0.05 was 
considered significant.
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